Form 4: Neumora CFO Sells Shares Under 10b5-1 Plan

Neumora Therapeutics CFO Michael Lee Milligan sold 1,436 shares of common stock to cover tax obligations under a pre-arranged 10b5-1 trading plan.

Summary

• Michael Lee Milligan, Chief Financial Officer and Principal Accounting Officer of Neumora Therapeutics, Inc. (NMRA), reported a sale of common stock.
• The transaction involved the disposition of 1,436 shares of Neumora Therapeutics common stock.
• The sale occurred on February 17, 2026, at a price of $3.565 per share.
• Following this transaction, Michael Lee Milligan beneficially owns 21,034 shares of common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted on August 30, 2024.
• The purpose of the sale was to satisfy applicable withholding obligations related to the vesting of restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine, non-discretionary transaction by an insider to satisfy tax obligations under a pre-arranged 10b5-1 plan, rather than a discretionary sale based on new information.

Management Comments

• The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on August 30, 2024, which provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered restricted stock unit in an amount necessary to satisfy the applicable withholding obligation.

Industry Context

StockSavvy.ai notes that Rule 10b5-1 trading plans are a common mechanism used by corporate insiders to sell company stock in a pre-arranged, non-discretionary manner. These plans help insiders avoid accusations of trading on material non-public information by scheduling sales in advance, often to cover tax obligations arising from equity compensation.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, non-discretionary transaction by an insider to cover tax obligations, not indicative of a change in company fundamentals or management's outlook.

Key Dates

Recommendation

The transaction is a routine, non-discretionary sale by an insider to cover tax withholding obligations under a pre-arranged 10b5-1 plan. It does not reflect a change in management's outlook or provide new fundamental information about the company, thus a 'hold' recommendation is appropriate.

Keywords

Neumora Therapeutics, NMRA, Form 4, Insider Transaction, Stock Sale, 10b5-1 Plan, CFO, Tax Withholding